Plant-based Medicago to be acquired by Mitsubishi Tanabe Pharma

Medicago has announced that it has agreed to be acquired by Japanese company Mitsubishi Tanabe Pharma Corp (MTPC). The Canadian biopharmaceutical company has been developing vaccines using virus-like particles (VLPs) extracted from tobacco plants, and recently announced positive pre-clinical data with its VLP vaccine candidate for H7N9 influenza. The deal would make Medicago a joint-venture firm of MTPC (60%) and …

Medicago “first in the world” to report positive pre-clinical data for H7N9 vaccine

Medicago has announced that it is "first in the world" to report positive interim results from a pre-clinical trial for an H7N9 Virus-Like Particle (VLP) vaccine candidate. The company reports that three micrograms of its H7 vaccine administered with and without adjuvant induced high antibody titres after one dose. According to Andy Sheldon, President and CEO of Medicago, the results …

IDRI and Medicago to present H5N1 vaccine data at the World Vaccine Congress

IDRI (Infectious Disease Research Institute) and Medicago Inc. have announced that they will be presenting positive interim Phase I clinical results of their H5N1 Avian Influenza VLP (Virus-Like Particles) vaccine candidate at the upcoming World Vaccine Congress, Washington DC. In the presentation, titled “H5N1 Phase 1 clinical trial combining Medicago’s VLP vaccine with IDRI’s GLA adjuvant formulation,” Dr Steven Reed, …